Trevena Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Trevena disminuyan a un ritmo anual de 10.8% y 2.9% respectivamente, mientras que se espera que el BPA crezca un 22.9% por año.

Información clave

-2.9%

Tasa de crecimiento de los beneficios

22.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	-10.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	02 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TRVN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-39	N/A	N/A	1
12/31/2025	9	-31	N/A	N/A	2
12/31/2024	N/A	-33	N/A	N/A	2
12/31/2023	3	-40	-33	-33	N/A
9/30/2023	3	-31	-38	-38	N/A
6/30/2023	3	-38	-39	-39	N/A
3/31/2023	0	-45	-44	-44	N/A
12/31/2022	0	-54	-52	-51	N/A
9/30/2022	0	-61	-53	-53	N/A
6/30/2022	0	-59	-54	-54	N/A
3/31/2022	0	-58	-54	-54	N/A
12/31/2021	1	-52	-50	-50	N/A
9/30/2021	1	-50	-45	-45	N/A
6/30/2021	3	-41	-36	-36	N/A
3/31/2021	3	-33	-30	-30	N/A
12/31/2020	3	-29	-21	-21	N/A
9/30/2020	3	-24	-21	-21	N/A
6/30/2020	0	-27	-25	-25	N/A
3/31/2020	0	-25	-22	-22	N/A
12/31/2019	0	-25	-24	-24	N/A
9/30/2019	0	-26	-22	-23	N/A
6/30/2019	3	-22	-20	-20	N/A
3/31/2019	6	-27	-23	-23	N/A
12/31/2018	6	-31	-26	-25	N/A
9/30/2018	6	-38	-32	-31	N/A
6/30/2018	3	-49	-41	-39	N/A
3/31/2018	N/A	-60	-56	-52	N/A
12/31/2017	N/A	-72	-75	-71	N/A
9/30/2017	N/A	-93	N/A	-87	N/A
6/30/2017	N/A	-107	N/A	-100	N/A
3/31/2017	2	-106	N/A	-100	N/A
12/31/2016	4	-103	N/A	-92	N/A
9/30/2016	6	-82	N/A	-76	N/A
6/30/2016	8	-63	N/A	-63	N/A
3/31/2016	8	-55	N/A	-55	N/A
12/31/2015	6	-51	N/A	-40	N/A
9/30/2015	4	-48	N/A	-41	N/A
6/30/2015	3	-53	N/A	-40	N/A
3/31/2015	1	-53	N/A	-40	N/A
12/31/2014	N/A	-50	N/A	-40	N/A
9/30/2014	N/A	-43	N/A	-37	N/A
6/30/2014	N/A	-37	N/A	-33	N/A
3/31/2014	0	-30	N/A	-28	N/A
12/31/2013	0	-24	N/A	-24	N/A
9/30/2013	0	-20	N/A	-17	N/A
6/30/2013	1	-15	N/A	-14	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TRVN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que TRVN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que TRVN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que TRVN no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que TRVN no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TRVN se prevé que sea elevada dentro de 3 años.

Trevena Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Consensus EPS estimates fall by 28%, revenue upgraded

Consensus revenue estimates increase by 725%

Price target decreased by 39% to US$17.00

Price target decreased to US$28.67

Consensus forecasts updated

Recent updates

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Trevena Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$28.67

Insufficient new directors

Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator

Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Trevena Gets an Additional 180 Days to Get Listing Compliance

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trevena, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform

Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk

Consensus forecasts updated

Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder

Trevena, Inc. Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

Trevena Investor Presentation - Slideshow

Trevena, Inc. Announces TRV027 Selected by NIH-Funded ACTIV Initiative for COVID-19 Trial

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Trevena, Inc. Publishes New Analysis of Respiratory Safety Data from the OLINVYK Phase 3 Multi-Site